Enzastaurin For Breast Cancer Patients Who Previously Received an Anthracycline and a Taxane Chemotherapy
Completed · Phase 2
Conditions studied: Breast Neoplasms
In brief
The purpose of this study is to determine the effectiveness of enzastaurin in the treatment of patients with metastatic breast cancer.
Key facts
- Study ID
- NCT00386087
- Run by
- Eli Lilly and Company
- People needed
- 41
- Starts
- 2006-11-01
- Expected to finish
- 2007-09-01
- Last updated by the study team
- 2008-06-06
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- Clinical diagnosis of metastatic breast cancer or recurrent breast cancer where surgery can not be done for curative intent
- Have received prior therapy with an anthracycline (class of drugs) and a taxane (class of drugs).
- Tumors must not be positive for HER2, but if positive, the treatment plan should not include further treatment with the drug Herceptin.
- Disease that can be definitely measured on Cat Scans or other radiological tests.
- May have received high dose chemotherapy for autologous stem cell support greater than or equal to 6 months of starting this study.
You may not qualify if…
- More than 2 chemotherapy regimens for metastatic or locally recurrent disease.
- Have brain cancer from breast cancer
- Pregnant or breastfeeding
- Have an inability to swallow tablets
- Within 6 months have had a serious heart condition
Where it is running
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. — Newark, Delaware, United States
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. — Indianapolis, Indiana, United States
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. — South Bend, Indiana, United States
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. — Boston, Massachusetts, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.